0 168

Cited 0 times in

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the Phase 3 MYSTIC study

DC Field Value Language
dc.contributor.author조병철-
dc.date.accessioned2020-12-08T01:52:02Z-
dc.date.available2020-12-08T01:52:02Z-
dc.date.issued2019-04-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180635-
dc.description.abstractBackground In MYSTIC (NCT02453282), an open-label, Phase 3 study of first-line D (anti-PD-L1) ± tremelimumab vs platinum-based CT in mNSCLC, while not statistically significant, a clinically meaningful improvement in OS was seen with D vs CT in pts with tumour cell PD-L1 expression ≥25% (PD-L1 TC ≥25%; HR 0.76 [97.54% CI 0.56–1.02], p=0.036). Here we describe subsequent treatment patterns and explore the effect of subsequent IO on the OS outcome with D vs CT. Methods IO/CT-naïve mNSCLC pts were randomised to D (20 mg/kg i.v. q4w until disease progression) or CT (up to 6 cycles; pemetrexed maintenance permitted). In-study crossover from CT to D was not allowed. For D vs CT, the primary endpoint was OS in pts with PD-L1 TC ≥25%. Three statistical models were employed in exploratory analyses to evaluate the effect of subsequent (post-study) IO on the OS data: the rank preserving structural failure time (RPSFT) method, the inverse probability of censoring weighting (IPCW) method, and a 2-stage method. Results 163 and 162 pts with PD-L1 TC ≥25% were randomised to D and CT, respectively. At data cut-off (04 Oct 2018), 44.8% of pts in the D arm and 58.6% of pts in the CT arm had received subsequent treatment (Table). Most pts started subsequent treatment within 2 mos of discontinuing study treatment. Among pts who received subsequent treatment, IO was administered to 10/73 (13.7%) pts in the D arm and 64/95 (67.4%) pts in the CT arm; most commonly nivolumab. Using the 2-stage method, which was the most appropriate for evaluating the effect of subsequent IO, OS was improved with D vs CT (HR 0.66 [95% CI 0.51, 0.86]).Table: LBA4-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEffect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the Phase 3 MYSTIC study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorB.C. Cho-
dc.contributor.googleauthorN. Reinmuth-
dc.contributor.googleauthorK.H. Lee-
dc.contributor.googleauthorM.-J. Ahn-
dc.contributor.googleauthorA. Luft-
dc.contributor.googleauthorM. Van den Heuvel-
dc.contributor.googleauthorM. Cobo Dols-
dc.contributor.googleauthorA. Smolin-
dc.contributor.googleauthorD. Vicente-
dc.contributor.googleauthorV. Moiseyenko-
dc.contributor.googleauthorS.J. Antonia-
dc.contributor.googleauthorS. Le Moulec-
dc.contributor.googleauthorG. Robinet-
dc.contributor.googleauthorR. Natale-
dc.contributor.googleauthorE.B. Garon-
dc.contributor.googleauthorK. Nakagawa-
dc.contributor.googleauthorF. Liu-
dc.contributor.googleauthorP. Thiyagarajah-
dc.contributor.googleauthorS. Peters-
dc.contributor.googleauthorN.A. Rizvi-
dc.identifier.doi10.1093/annonc/mdz094-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753419302613-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume30-
dc.citation.numberSuppl.2-
dc.citation.startPageii79-
dc.citation.endPageii80-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.30(Suppl.2) : ii79-ii80, 2019-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.